Trials / Completed
CompletedNCT00238485
An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750-2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder
A 52-week, Open Label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750 - 2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 251 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This extension study is designed to investigate the long-term safety and tolerability of licarbazepine 750-2000 mg/d over 52 weeks in patients who completed the 6-week double-blind study CLIC477D2302.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Licarbazepine |
Timeline
- Start date
- 2005-01-01
- Primary completion
- 2007-07-01
- Completion
- 2007-07-01
- First posted
- 2005-10-13
- Last updated
- 2017-03-28
Source: ClinicalTrials.gov record NCT00238485. Inclusion in this directory is not an endorsement.